Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson's Disease.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2021
Historique:
pubmed: 29 12 2020
medline: 21 1 2022
entrez: 28 12 2020
Statut: ppublish

Résumé

Cognitive and sleep dysfunction are common non-motor symptoms in Parkinson's disease (PD). Determine the relationship between slow wave sleep (SWS) and cognitive performance in PD. Thirty-two PD participants were evaluated with polysomnography and a comprehensive level II neurocognitive battery, as defined by the Movement Disorders Society Task Force for diagnosis of PD-mild cognitive impairment. Raw scores for each test were transformed into z-scores using normative data. Z-scores were averaged to obtain domain scores, and domain scores were averaged to determine the Composite Cognitive Score (CCS), the primary outcome. Participants were grouped by percent of SWS into High SWS and Low SWS groups and compared on CCS and other outcomes using 2-sided t-tests or Mann-Whitney U. Correlations of cognitive outcomes with sleep architecture and EEG spectral power were performed. Participants in the High SWS group demonstrated better global cognitive function (CCS) (p = 0.01, effect size: r = 0.45). In exploratory analyses, the High SWS group showed better performance in domains of executive function (effect size: Cohen's d = 1.05), language (d = 0.95), and processing speed (d = 1.12). Percentage of SWS was correlated with global cognition and executive function, language, and processing speed. Frontal EEG delta power during N3 was correlated with the CCS and executive function. Cognition was not correlated with subjective sleep quality. Increased SWS and higher delta spectral power are associated with better cognitive performance in PD. This demonstrates the significant relationship between sleep and cognitive function and suggests that interventions to improve sleep might improve cognition in individuals with PD.

Sections du résumé

BACKGROUND
Cognitive and sleep dysfunction are common non-motor symptoms in Parkinson's disease (PD).
OBJECTIVE
Determine the relationship between slow wave sleep (SWS) and cognitive performance in PD.
METHODS
Thirty-two PD participants were evaluated with polysomnography and a comprehensive level II neurocognitive battery, as defined by the Movement Disorders Society Task Force for diagnosis of PD-mild cognitive impairment. Raw scores for each test were transformed into z-scores using normative data. Z-scores were averaged to obtain domain scores, and domain scores were averaged to determine the Composite Cognitive Score (CCS), the primary outcome. Participants were grouped by percent of SWS into High SWS and Low SWS groups and compared on CCS and other outcomes using 2-sided t-tests or Mann-Whitney U. Correlations of cognitive outcomes with sleep architecture and EEG spectral power were performed.
RESULTS
Participants in the High SWS group demonstrated better global cognitive function (CCS) (p = 0.01, effect size: r = 0.45). In exploratory analyses, the High SWS group showed better performance in domains of executive function (effect size: Cohen's d = 1.05), language (d = 0.95), and processing speed (d = 1.12). Percentage of SWS was correlated with global cognition and executive function, language, and processing speed. Frontal EEG delta power during N3 was correlated with the CCS and executive function. Cognition was not correlated with subjective sleep quality.
CONCLUSION
Increased SWS and higher delta spectral power are associated with better cognitive performance in PD. This demonstrates the significant relationship between sleep and cognitive function and suggests that interventions to improve sleep might improve cognition in individuals with PD.

Identifiants

pubmed: 33361608
pii: JPD202215
doi: 10.3233/JPD-202215
pmc: PMC8058231
mid: NIHMS1650606
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

703-714

Subventions

Organisme : NICHD NIH HHS
ID : P2C HD086851
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003096
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD071866
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000165
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS080912
Pays : United States
Organisme : NINDS NIH HHS
ID : R25 NS079188
Pays : United States

Références

Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Sleep Med Rev. 2018 Apr;38:39-49
pubmed: 28760549
Nat Rev Neurosci. 2010 Feb;11(2):114-26
pubmed: 20046194
Sleep. 2009 Oct;32(10):1273-84
pubmed: 19848357
Psychophysiology. 2003 May;40(3):349-57
pubmed: 12946109
J Sleep Res. 2016 Jun;25(3):296-306
pubmed: 26853796
J Am Geriatr Soc. 2000 Aug;48(8):938-42
pubmed: 10968298
Mov Disord. 2020 Jun;35(6):947-958
pubmed: 32092190
Science. 2013 Oct 18;342(6156):373-7
pubmed: 24136970
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Brain. 2016 Apr;139(Pt 4):1189-99
pubmed: 26912643
Psychol Aging. 2013 Mar;28(1):105-14
pubmed: 22708533
Arch Intern Med. 2004 Feb 23;164(4):406-18
pubmed: 14980992
Sports Med. 1996 Apr;21(4):277-91
pubmed: 8726346
JAMA Neurol. 2013 Dec;70(12):1544-51
pubmed: 24145819
Mov Disord. 2006 Sep;21(9):1432-8
pubmed: 16773617
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Brain Res Bull. 2003 Dec 15;62(2):143-50
pubmed: 14638388
Arch Neurol. 2008 Oct;65(10):1337-40
pubmed: 18852348
Sleep Med Rev. 2017 Oct;35:33-50
pubmed: 27863901
JAMA Neurol. 2018 Jan 1;75(1):114-118
pubmed: 29114733
Nature. 2006 Nov 30;444(7119):610-3
pubmed: 17086200
Nat Neurosci. 2000 Dec;3(12):1335-9
pubmed: 11100156
Sleep Med. 2021 Jan;77:205-208
pubmed: 32847743
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Science. 2019 Nov 1;366(6465):628-631
pubmed: 31672896
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Ann Neurol. 2008 Dec;64 Suppl 2:S65-80
pubmed: 19127582
Mov Disord. 2011 Feb 15;26(3):399-406
pubmed: 21264941
Neurobiol Aging. 2015 Feb;36(2):1083-90
pubmed: 25442116
Mov Disord Clin Pract. 2017 Mar-Apr;4(2):183-190
pubmed: 28924578
Nat Rev Neurosci. 2002 Sep;3(9):679-93
pubmed: 12209117
Front Hum Neurosci. 2017 Mar 08;11:109
pubmed: 28337134
Behav Sleep Med. 2016;14(3):295-310
pubmed: 26322904
Am J Geriatr Psychiatry. 2011 Apr;19(4):374-81
pubmed: 20808148
Sci Adv. 2019 Feb 27;5(2):eaav5447
pubmed: 30820460
Nature. 2005 Oct 27;437(7063):1272-8
pubmed: 16251952
J Geriatr Psychiatry Neurol. 2012 Dec;25(4):208-14
pubmed: 23172765
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317
Trends Neurosci. 2018 Jul;41(7):470-482
pubmed: 29628198

Auteurs

Kimberly H Wood (KH)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Psychology, Samford University, Birmingham, AL, USA.

Adeel A Memon (AA)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Raima A Memon (RA)

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.

Allen Joop (A)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Jennifer Pilkington (J)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Corina Catiul (C)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Adam Gerstenecker (A)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Kristen Triebel (K)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Gary Cutter (G)

Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.

Marcas M Bamman (MM)

Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Geriatric Research, Education, and Clinical Center, Birmingham VA Medical Center, Birmingham, AL, USA.

Svjetlana Miocinovic (S)

Department of Neurology, Emory University, Atlanta, GA, USA.

Amy W Amara (AW)

Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH